1. Home
  2. Directory
  3. Maryland
  4. Baltimore
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1467733113

DR. PATRICK FORDE M.D.
Prescription History 1467733113
Internal Medicine - Hematology & Oncology in Baltimore, MD


Quality Rating: 74.39 out of 100 score

NPI Status: Active since September 07, 2011

Contact Information

401 NORTH BROADWAY
WEINBERG BDG.
BALTIMORE, MD
ZIP 21231
Phone: (410) 955-3974

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. PATRICK FORDE M.D., an active Hematology & Oncology specialist practicing in Baltimore, MD. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 89 documented patient claims. Among these therapy options, the most frequently utilized medication is Tagrisso, which accounts for 26 claims alone.

Medication Index

E
P
T
X
No matching medications currently found on file.

Eliquis

Generic Formulation: ApixabanSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
MD State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills112.6
Peer Average Days Supply3,167
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.0% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,066.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$543.56

State Avg Cost Per Claim

$880.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Prednisone

Generic Formulation: PrednisoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.5
Days Supply 228
MD State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills50.6
Peer Average Days Supply992
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.2% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $160.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.41

State Avg Cost Per Claim

$7.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 124
MD State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.6
Peer Average Days Supply315
Conservative Utilization

This provider writes prescriptions for this formulation 34.6% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $187.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.03

State Avg Cost Per Claim

$16.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Tagrisso

Generic Formulation: Osimertinib MesylateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 780
MD State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.9
Peer Average Days Supply685
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $463,305.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,819.46

State Avg Cost Per Claim

$16,919.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

Xalkori

Generic Formulation: CrizotinibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
MD State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.4
Peer Average Days Supply471
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 31.3% more claims than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $428,666.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,412.71

State Avg Cost Per Claim

$16,412.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.

Therapeutic Applications

Crizotinib is used to treat certain types of cancer (such as lung cancer, anaplastic large cell lymphoma-ALCL). It is also used to treat a certain type of tumor (inflammatory myofibroblastic tumor-IMT). Crizotinib works by slowing or stopping the growth of cancer or tumor cells. It belongs to a class of drugs known as kinase inhibitors.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. PATRICK FORDE M.D. provides transparency into local medical care patterns within Baltimore, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.